Day One’s Ojemda Gets FDA Accelerated Approval for Pediatric Brain Tumor
Pictured: Facade of the FDA's office in Maryland/iStock, Grandbrothers Day One Biopharmaceuticals on Tuesday announced that it has secured the FDA’s accelerated approval for tovorafenib, which will be marketed under the brand name Ojemda, for the …